Catamaran Bio selects OmniaBio as partner to develop CAR-NK cell therapies
14 Mar 2023 //
BUSINESSWIRE
Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies
14 Mar 2023 //
CONTRACT PHARMA
Funding from Ontario Government Launches OmniaBio
01 Apr 2022 //
CONTRACTPHARMA
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results
25 Aug 2020 //
BUSINESSWIRE